JAVIER ALONSO-LLAMAZARES, M.D. v. INTERNATIONAL DERMATOLOGY RESEARCH, INC., etc. ( 2022 )

Third District Court of Appeal
State of Florida
Opinion filed January 19, 2022.
Not final until disposition of timely filed motion for rehearing.
________________
No. 3D20-0985
Lower Tribunal No. 20-3662
________________
Javier Alonso-Llamazares, M.D.,
Appellant,
vs.
International Dermatology Research, Inc., etc.,
Appellee.
An Appeal from a non-final order from the Circuit Court for Miami-Dade
County, Valerie R. Manno Schurr, Judge.
Ainsworth + Clancy, PLLC, and Janna O. Mateo and Ryan M. Clancy,
for appellant.
Feiler & Leach, P.L., and Martin E. Leach, for appellee.
Before HENDON, MILLER and LOBREE, JJ.
LOBREE, J.
This appeal stems from a non-compete agreement entered into
between appellant Javier Alonso-Llamazares, M.D. (“Dr. Alonso”) and his
former employer, appellee International Dermatology Research Inc. (“IDR”).
After IDR terminated Dr. Alonso’s employment, IDR sought, and was
granted, a temporary injunction enforcing the parties’ non-compete
agreement. We affirm the trial court’s determination that the non-compete
agreement was enforceable and the requirements for a temporary injunction
were established, but reverse and remand for the trial court to describe in
reasonable detail the act or acts restrained as required by Florida Rule of
Civil Procedure 1.610(c).
Background Facts and Procedural History
IDR is a medical practice management business that utilizes
dermatologists to conduct clinical research projects in the area of
dermatology. On October 4, 2011, IDR and Dr. Alonso entered into an
Agreement for Management Services and Clinical Research Services (the
“Agreement”). Under the Agreement, IDR agreed to provide certain
management services to Dr. Alonso’s dermatological medical practice. Dr.
Alonso, in turn, agreed to conduct clinical research projects for and on behalf
of IDR. Because this case concerns interpretation of the terms of the
Agreement, relevant sections are set forth at length below. Section 3 of the
Agreement is entitled “Term” and provides in relevant part as follows:
2
Unless terminated earlier pursuant to Section 11 of this
Agreement, the term of engagement under this Agreement shall
be for a period of two (2) year [sic] commencing on the Effective
Date and ending on the first anniversary of the Effective Date
(the “Term”).
Section 11 of the Agreement, entitled “Termination,” provides in part as
follows:
11.1 Termination by Company. Company shall be entitled to
terminate this Agreement, upon written notice to Physician, at
any time for any or no reason.
11.2 Termination by Physician. . . .
11.3 Effects of Termination. Upon the termination of this
Agreement:
(a) Physician’s duties and Company’s obligations shall
cease as of the effective date of termination, provided, however,
that the Physician shall in all events of termination be responsible
for arranging for the smooth transition of Physician’s duties to
appropriate employees or contractors of Company and all duties
and obligations of Physician intended to survive termination shall
survive (including Physician’s obligations under Sections 8, 9.9,
12 and 13 of this Agreement).
(emphasis in original). Dr. Alonso also agreed to a non-compete provision
in section 12 of the Agreement that required the following:
12. Non-Competition and Confidentiality. Physician
acknowledges that incident to Physician’s engagement,
Physician will gain extensive and valuable experience and
knowledge relating to Company and the Company’s business
and will have access to confidential information relating to the
business and operations of Company, the use or disclosure of
which would cause Company substantial loss and damages that
would not be readily calculated and for which no remedy at law
3
would be adequate. Accordingly, as a material inducement to
Company’s entering into this Agreement, Physician hereby
covenants as follows:
12.1 Non-Competition. During the Term of this
Agreement and thereafter for a period of two (2) years (the
''Post-Term Restrictive Period") from the date of expiration
or termination of the Term of this Agreement for any reason
whatsoever, Physician shall not directly or indirectly, on
Physician’s own behalf or as a principal, partner, member,
shareholder, officer, employee, agent, consultant, contractor,
physician, director or trustee of any person, partnership, firm,
association, corporation, hospital, clinic or other medical facility:
(i) engage in the practice of medicine anywhere within a two (2)
mile radius of the Premises provided by the Company for the
operation of the Practice; (ii) perform, conduct, promote, market,
exploit, participate in, engage in or otherwise be involved with, or
engage in any business that directly or indirectly performs,
conducts, promotes, markets, exploits or engages in or is
otherwise involved in, clinical research or trials relating to
dermatology including, without limitation, dermatological
products or procedures, anywhere within a five (5) mile radius of
the Premises provided by the Company for the operation of the
Practice; (iii) attempt to solicit or solicit or otherwise contact the
patients, customers or clients (including any pharmaceutical
companies or manufacturers) of Company or other physician
practices managed by Company or use patient or customer lists
developed or owned by Company or other physician practices
managed by Company; or (iv) divert or attempt to divert from
Company or other physician practices managed by Company
any business or business opportunity whatsoever or accept any
business from any patients, customers or clients (including any
pharmaceutical companies or manufacturers) of Company or
other physician practices managed by Company; provided that,
Physician may conduct any clinical studies that are not the same
as or similar to the types of studies conducted by the Company
(as determined by the Company), provided Physician first
obtains the Company’s written consent to each such study. . . .
12.2 Confidentiality of Patient and Client Information. . . .
4
12.3 Enforcement. Physician acknowledges and agrees
that irreparable injury will result to Company in the event of
Physician’s breach of any covenant set forth in this Section 12,
that a material inducement to Company’s engagement of
Physician is the covenants set forth in Section 12, and that
monetary damages in an action at law would not provide an
adequate remedy in the event of a breach of this Section 12.
Physician further acknowledges and agrees that the covenants
contained in Section 12 are necessary for the protection of
Company’s legitimate business and professional duties, ethical
obligations, and interest, and are reasonable in scope and
content and have been negotiated in good faith and on an arms-
length basis. In the event of Physician’s breach or threatened
breach of Section 12, this Section may be enforced by the
obtaining of an injunction to restrain the violation thereof by
Physician.
12.4 Survival. The covenants of this Section 12 shall
survive the expiration or termination of this Agreement.
(bold emphasis added) The parties continued their relationship when the
Agreement expired in 2013. On January 4, 2016, the parties executed an
Amendment to Agreement (the “First Amendment”), modifying provisions of
the Agreement, including that the Term of the engagement under the
Agreement is through December 31, 2016. The First Amendment also
stated that all other aspects of the Agreement remained in effect, including
section 12. Then, on January 4, 2017, the parties executed a Second
Amendment to Agreement (the “Second Amendment”). The Second
Amendment provided that “the term of the engagement under this
Agreement shall be through December 31, 2017 (the ‘Term’).” As with the
5
First Amendment, apart from other modifications made by the Second
Amendment, the Agreement remained in effect, including but not limited to
section 12. Finally, on June 1, 2017, the parties executed the Third
Amendment to Agreement (the “Third Amendment”). The Third Amendment
made changes to Dr. Alonso’s hours and compensation but did not modify
the Term. The Third Amendment also provided that “[i]n all other respects,
the Agreement, the First Amendment and the Second Amendment remain in
full force and effect, including, but not limited to, Section 12-Non-Competition
and Confidentiality.”
Dr. Alonso continued to work for IDR after December 31, 2017.
Subsequently, IDR notified Dr. Alonso by letter that “as of November 1, 2019,
your services are no longer required at [IDR].”1 Dr. Alonso then began
operating Driven Research LLC on January 2, 2020. Dr. Alonso does not
dispute that he began Driven Research to conduct clinical trials and that as
of January 2, 2020, he was competing with IDR.
Shortly thereafter, on February 12, 2020, IDR filed suit against Dr.
Alonso, seeking temporary and permanent injunctions and asserting claims
for breach of contract and tortious interference with contractual relations
1
Although the letter is undated, the parties stipulated that IDR “terminated
[Dr. Alonso’s] employment on November 1, 2019, through a written letter.”
6
based on Dr. Alonso’s active competition against IDR. IDR moved for
emergency injunctive relief, arguing that Dr. Alonso breached section 12 of
the Agreement by competing with IDR and soliciting IDR’s customers and
clients. IDR argued that it was entitled to an injunction because section
542.335(1)(j), Florida Statutes (2017), 2 provides that irreparable harm is
presumed when a party establishes the violation of an enforceable restrictive
covenant. IDR also asserted that it did not have an adequate remedy at law.
IDR argued that it had a likelihood of success on the merits because the
Agreement contained an enforceable non-compete provision and further
argued that the granting of a temporary injunction was not against the public
interest because public policy favors the enforcement of contracts and non-
compete agreements, as evidenced by section 542.335. IDR sought to
enjoin Dr. Alonso from: (1) working with Driven Research; (2) directly or
indirectly competing with IDR for a period of two years; (3) being involved in
clinical research or trials relating to dermatological products or procedures
2
A non-compete provision “is governed by the statute existing when it was
executed.” White v. Mederi Caretenders Visiting Servs. of Se. Fla., LLC, 226
So. 3d 774, 777 n.1 (Fla. 2017). Here, the Third Amendment, which stated
that “[i]n all other respects, the Agreement, the First Amendment and the
Second Amendment remain in full force and effect, including, but not limited
to, Section 12-Non-Competition and Confidentiality,” was entered into in
2017. As noted in White, there have been no amendments to section
542.335 since its enactment in 1996. Id.7
for a period of two years within a five-mile radius; (4) attempting to solicit or
soliciting or contacting IDR’s patients, customers, or clients for a period of
two years; (5) using patient or customer lists developed by IDR. IDR also
demanded that Dr. Alonso to turn over any of IDR’s confidential information
in his possession.
Dr. Alonso responded that IDR did not have a likelihood of success on
the merits because the post-term restrictive period was not in effect on
January 2, 2020, when he began working for Driven Research. Specifically,
Dr. Alonso argued that the Agreement expired on December 31, 2017,
“meaning that the Restrictive Covenant would be in full force and effect for
two years from the end of the Term (December 31, 2019).” Thus, Dr. Alonso
asserted, “[t]he expiration date for the Non-Compete clause is December 31,
2019,” and he was not in breach of the non-compete provision when he
began working for Driven Research. Dr. Alonso denied soliciting IDR’s
clients, but stated that even if he had, this was permissible because the non-
compete provision had expired. Dr. Alonso further argued that IDR could not
show irreparable harm because after December 31, 2019, he was free to
compete with IDR. As to whether the public interest would be served by
granting an injunction, Dr. Alonso stated that the public interest would not be
8
served by enforcing an expired contract and that enjoining medical research
“for the most part” is not in the public interest.
The trial court held an evidentiary hearing to address IDR’s motion.
IDR argued that the non-compete provision was reasonable in length and
geographic limitation. IDR also asserted that the non-compete provision was
in effect on January 2, 2020, because section 12.4 of the Agreement
provides that “[t]he covenants of this Section 12 shall survive the expiration
or termination of this Agreement.” Under section 12.4, the non-compete
provision survived the expiration of the Agreement and the two-year period
of restraint was then triggered on November 1, 2019, when IDR terminated
Dr. Alonso’s employment in accordance with section 11.1. In response, Dr.
Alonso argued that the non-compete provision was not valid because under
the clear language of the Agreement, the Agreement expired on December
31, 2017, and the non-compete provision lasts for two years thereafter,
ending on December 31, 2019. Dr. Alonso maintained that reading section
12.1 and 12.4 together, the non-compete restraints in 12.1 survive for only
two years after expiration of the term of the Agreement.
At the hearing, the trial court heard testimony from Dr. Alonso and
Silvia Trinidad (“Trinidad”), the president and CEO of IDR. Trinidad testified
that prior to working with IDR, Dr. Alonso had not worked in clinical trials that
9
were regulated by the FDA, and that IDR trained him in that area. IDR also
paid for Dr. Alonso to attend conferences to introduce him to and foster his
relationship with pharmaceutical companies and contract research
organizations. 3 Significantly, Trinidad also testified that Dr. Alonso had sent
a letter to one of IDR’s clients in which he requested work from that client
and for the client to visit him. Trinidad testified that Dr. Alonso obtained a list
of IDR’s clients, patients and subjects for trials, contract research
organizations, and the prices IDR charges for studies it conducts. Trinidad
asserted that Dr. Alonso obtained this information through IDR employees
who he “took from IDR” and are working for him. Trinidad also testified that
former patients of IDR had called IDR to make appointments for a study Dr.
Alonso was conducting after they were contacted by someone at Dr.
Alonso’s office who had previously worked at IDR. On cross-examination,
Trinidad acknowledged that while at IDR, Dr. Alonso did not have access to
a computer containing the list of patients or prices.
Dr. Alonso testified that prior to working at IDR, he had been involved
in two clinical studies. He also testified that when he worked at IDR, and
now at Driven Research, he does not have access to a patient database.
3
Trinidad explained that contract research organizations are a liaison
between pharmaceutical companies and researchers.
10
On cross-examination, Dr. Alonso admitted that he is competing with IDR. 4
The trial court granted IDR’s motion for a temporary injunction. First,
the trial court found that the non-compete provision was enforceable. The
trial court found that the provision was supported by three legitimate
business interests: (1) valuable confidential business information; (2)
substantial relationships with specific prospective or existing customers; and
(3) specialized training. The trial court further found that Dr. Alonso “failed
to assert any sufficient challenge to the geographic scope or the duration of
the Non-Compete Agreement, or the scope of activity prohibited by it.” As
to Dr. Alonso’s argument that the non-compete provision had expired, the
trial court found that under section 12.4, the non-compete provision survived
the expiration of the Agreement where Dr. Alonso continued to work at IDR.
Second, the trial court determined that the requirements for a
temporary injunction had been satisfied. The trial court found that: (1) IDR
will continue to suffer immediate and irreparable harm if Dr. Alonso is not
prohibited from additional breaches and Dr. Alonso did not rebut the statutory
presumption of irreparable harm under section 542.335(1)(j); (2) IDR has a
substantial likelihood of success on its claim that Dr. Alonso breached
4
Dr. Alonso stated, “First of all, I’m not competing with the plaintiff only. I’m
competing with every clinical researcher in Miami.”
11
section 12 of the Agreement; (3) IDR did not have an adequate remedy at
law; and (4) the temporary injunction will further the public interest in IDR’s
ability to protect its investment in its own business information and Dr.
Alonso made no showing that a specific public policy requirement
substantially outweighed the need to protect IDR’s legitimate business
interest.
Dr. Alonso moved for reconsideration and, in the alternative, for a stay
pending review, reasserting his argument that he was not subject to the non-
compete provision on January 2, 2020, because it expired on December 31,
2019. In support of his motion for stay pending review, Dr. Alonso attached
an affidavit stating that Driven Research will be in non-compliance with the
FDA if he does not oversee the research and that patients could be left
without proper medical supervision unless a stay is issued. After a hearing,
the trial court denied Dr. Alonso’s motion for reconsideration and deferred
ruling on the stay. Dr. Alonso’s appeal from the trial court’s order granting a
temporary injunction and the denial of his motion for reconsideration
followed. 5
5
We have jurisdiction to review the non-final order granting the temporary
injunction under Florida Rule of Appellate Procedure 9.130(a)(3)(B).
Because the order denying Dr. Alonso’s motion for reconsideration was
entered and appealed within 30 days from the entry of the temporary
12
Standard of Review
“The standard of review of trial court orders on requests for temporary
injunctions is a hybrid. To the extent the trial court’s order is based on factual
findings, we will not reverse unless the trial court abused its discretion;
however, any legal conclusions are subject to de novo review.” Gainesville
Woman Care, LLC v. State, 210 So. 3d 1243, 1258 (Fla. 2017) (quoting Fla.
High Sch. Athletic Ass’n v. Rosenberg ex rel. Rosenberg, 117 So. 3d 825,
826 (Fla. 4th DCA 2013)); accord Fla. Dep’t of Health v. Florigrown, LLC,
317 So. 3d 1101, 1110 (Fla. 2021) (“We review a trial court’s factual findings
on the[] elements [of a claim for a temporary injunction] for competent,
substantial evidence, and we review its legal conclusions de novo. To the
extent the decision to enter a temporary injunction involves an exercise of
discretion, we defer to the trial court unless it has abused its discretion.”
(citation omitted)); see also Briceño v. Bryden Invs., Ltd., 973 So. 2d 614,
616 (Fla. 3d DCA 2008) (“A trial court has wide discretion to grant or deny a
temporary injunction and an appellate court will not interfere with the
exercise of such discretion unless the party challenging the grant or denial
clearly shows an abuse of that discretion.”(quoting Perry & Co. v. First Sec.
injunction, that order is also properly on review. Panama City Gen. P’ship v.
Godfrey Panama City Inv., LLC, 109 So. 3d 291, 291 (Fla. 1st DCA 2013).
13
Ins. Underwriters, Inc., 654 So. 2d 671, 671 (Fla. 3d DCA 1995))). “An
appellant who challenges the trial court’s order on a motion for temporary
injunction has a heavy burden; the trial court’s ruling is presumed to be
correct and can only be reversed where it is clear the court abused its
discretion.” Atomic Tattoos, LLC v. Morgan, 45 So. 3d 63, 64 (Fla. 2d DCA
2010).
Analysis
To obtain a temporary injunction, a party must establish “(1) a
substantial likelihood of success on the merits, (2) the unavailability of an
adequate remedy at law, (3) irreparable harm absent entry of an injunction,
and (4) that the injunction would serve the public interest.” Florigrown, LLC,
317 So. 3d at 1110.6 Relevant here, section 542.335(1)(j), Florida Statutes,
provides that a court shall enforce a valid “restrictive covenant by any
appropriate and effective remedy, including, but not limited to, temporary and
permanent injunctions.” See also Ansaarie v. First Coast Cardiovascular
Inst., P.A., 252 So. 3d 287, 290 (Fla. 1st DCA 2018) (“A temporary injunction
is an available remedy when a party establishes that it has a valid,
enforceable restrictive covenant that was violated.”). Further, “[t]he violation
6
We affirm without discussion Dr. Alonso’s challenge that the elements for
a temporary injunction were not satisfied here.
14
of an enforceable restrictive covenant creates a presumption of irreparable
injury to the person seeking enforcement of a restrictive covenant.” §
542.335(1)(j).
To be enforceable, a restrictive covenant must be reasonable with
regard to “time, area, and line of business” and “set forth in a writing signed
by the person against whom enforcement is sought.” § 542.335(1)(a).
Additionally, “[i]n Florida, a contract providing restrictions on competition
must involve a legitimate business interest as defined by statute to be
enforceable.” White, 226 So. 3d at 779; see § 542.335(1)(b), Fla. Stat.
(stating that “[t]he person seeking enforcement of a restrictive covenant shall
plead and prove the existence of one or more legitimate business interests
justifying the restrictive covenant” and providing non-exhaustive list of
legitimate business interests). “[T]he determination of whether an activity
qualifies as a protected legitimate business interest under the statute is
inherently a factual inquiry, which is heavily industry—and context-specific.”
White, 226 So. 3d at 786. A party seeking a temporary injunction also must
“plead and prove that the contractually specified restraint is reasonably
necessary to protect the legitimate business interest or interests justifying
the restriction.” § 542.335(1)(c). Once a party establishes a prima facie case
that the restriction is reasonably necessary, “the person opposing
15
enforcement has the burden of establishing that the contractually specified
restraint is overbroad, overlong, or otherwise not reasonably necessary to
protect the established legitimate business interest or interests.” Id. Finally,
the statute provides that courts must construe restrictive covenants “in favor
of providing reasonable protection to all legitimate business interests
established by the person seeking enforcement,” and without application of
“any rule of contract construction that requires the court to construe a
restrictive covenant narrowly, against the restraint, or against the drafter of
the contract.” § 542.335(1)(h).
On appeal, Dr. Alonso argues that the trial court erred in finding that
the non-compete provision was valid and enforceable. Specifically, Dr.
Alonso asserts that the non-compete provision expired before he began
working for Driven Research and that the trial court abused its discretion in
finding that the non-compete provision was supported by a legitimate
business interest. Neither of Dr. Alonso’s arguments is persuasive.
Dr. Alonso contends that because the Agreement and its Amendments
expired on December 31, 2017, section 12.1’s non-compete provision ended
on December 31, 2019, which was “two (2) years (the ‘Post-Term Restrictive
Period’) from the date of expiration or termination of the Term of this
Agreement.” Thus, Dr. Alonso claims he was free to begin working for Driven
16
Research, unrestrained by the non-compete provision, on January 2, 2020,
two months after his November 1, 2019, termination from IDR. Given the
plain language of the Agreement, we disagree with Dr. Alonso.
“This Court has held that post-termination restrictions expire upon the
termination of an agreement for a specific term, even if an employee remains
an at-will employee after the term of the written agreement expires.” Zupnik
v. All Fla. Paper, Inc., 997 So. 2d 1234, 1238 (Fla. 3d DCA 2008). This
principle applies where the restrictive covenant provides that it applies
following termination of employment and the parties’ agreement does not
expressly provide that the covenant survives the expiration of the
employment contract. See id. (holding that where non-compete provision
applied “during the [two-year] Employment Term and within twelve (12)
months from the termination of said term” and parties’ agreement did not
“contain language specifying that the restrictive covenants would continue
beyond the two-year term if [employee]” continued working, non-compete
provision expired at end of two-year employment term even where employee
continued working beyond that point); Sanz v. R.T. Aerospace Corp., 650
So. 2d 1057, 1059 (Fla. 3d DCA 1995) (reversing preliminary injunction in
favor of employer where restrictive covenants applied “during the existence
of [employee’s] employment and for a period of twenty-four (24) months
17
immediately following the termination of his employment” and employee
continued to work for employer after employment agreement expired
because covenants “were only applicable if [employee] terminated his
employment . . . during the life of the written agreement”). If, however, an
employment agreement contains express language showing that the parties
intend for a non-compete provision to survive the expiration or termination of
the agreement, the provision remains effective where the agreement expires
but the employment relationship continues. See St. Johns Inv. Mgmt. Co. v.
Albaneze, 22 So. 3d 728, 732 (Fla. 1st DCA 2009) (finding that language in
contract showed that parties intended non-compete provision to survive
employee’s post-term employment); Brenner v. Barco Chems. Div., Inc., 209
So. 2d 277, 278 (Fla. 3d DCA 1968) (affirming decree restraining employee
who resigned 18 months after contract expired where non-compete provision
applied during term of employment “and for a period of one year immediately
following the Expiration or termination of such employment by mutual
agreement” and contract provided that it would govern parties’ relations if
employee was retained by employer after expiration of contract); Sanz, 650
So. 2d at 1059 (rejecting appellee’s argument that non-compete covenants
survived expiration of agreement because “the fact that the noncompete
clauses were independent of other covenants in the agreement does not
18
mean that they survived the expiration of the contract in the absence of an
express provision to that effect” (emphasis added)); cf. Century 21 Real Est.
of S. Fla., Inc. v. Braun & May Realty, Inc., 706 So. 2d 878, 879 (Fla. 3d DCA
1997) (holding that termination triggered provision in agreement requiring
commission payments even though agreement had expired because “the
agreements provided that the parties continued to be bound by the
agreement terms”). Here, section 12.4 of the Agreement provides as follows:
“Survival. The covenants of this Section 12 shall survive the expiration or
termination of this Agreement.” Given the above principles, we conclude that
the express language of section 12.4 shows that the parties intended the
non-compete provision contained in section 12.1 to remain effective after the
Agreement’s expiration. 7 Thus, the non-compete provision survived the
December 31, 2017, expiration and was triggered upon IDR’s termination of
Dr. Alonso’s employment on November 19, 2019.
Dr. Alonso insists that this Court’s opinion in Brenner, 209 So. 2d at
277, holds that in order for a non-compete provision to survive post-term, the
contract must also expressly state that its terms apply if the employee
7
Dr. Alonso asserts that section 12.4 applies only to sections 12.2 and 12.3,
serving to “extend out” those sections, which do not contain two-year
limitations. Section 12.4, however, states that it applies to “[t]he covenants
of this Section.”
19
continues to work for the employer after expiration of the contract. Brenner
makes no such holding. In Brenner, the parties’ contract “provided for non
competition by Brenner ‘during the term of his employment by company and
for a period of one year immediately following the Expiration or termination
of such employment by mutual agreement.’” Id. at 278. The contract also
provided that “[i]n case the services of SALES MANAGER (Brenner) are
retained by COMPANY after the expiration of this contract without formal
contract, it is hereby mutually agreed that the terms of this contract shall
continue to govern the relations between COMPANY and SALES
MANAGER.” Id. Brenner continued to work for his employer after the
contract between the parties expired, but eventually resigned. This Court
affirmed the trial court’s decree restraining him from competing with his
former employer for one year after his resignation. In reaching its holding,
Brenner contains little analysis, only distinguishing between the non-
compete at issue, which applied following the expiration or termination of
employment, with the non-compete at issue in Storz Broadcasting Co. v.
Courtney, 178 So. 2d 40, 41 n.2 (Fla. 3d DCA 1965), which applied “upon
termination of his employment with the Company.” This Court’s conclusion
did not rest on a finding that where a contract, like here, expressly provides
that the non-compete covenants survive expiration or termination, the
20
contract must also state that its terms apply after expiration if the employee
continues to work for the employer. Even so, it is clear based on the
language of the Agreement that the parties contemplated continued
employment by Dr. Alonso. Section 12.4 states that the covenants in section
12 “survive the expiration or termination of this Agreement.” Section 12.1, in
contrast, uses the phrase “termination of the Term of this Agreement.”
(emphasis added). Termination of the Term of the Agreement is December
31, 2017. If, in the survival provision, section 12.4, the parties had intended
the covenants to survive only as measured from December 31, 2017, they
would have used the phrase, “termination of the Term of this Agreement,” as
they did in section 12.1. See Beach Towing Servs., Inc. v. Sunset Land
Assocs., LLC, 278 So. 3d 857, 861 (Fla. 3d DCA 2019) (stating that “[a]s a
general proposition, the use of different language in different contractual
provisions strongly implies that a different meaning was intended” (quoting
Fowler v. Gartner, 89 So. 3d 1047, 1048 (Fla. 3d DCA 2012))). Moreover,
the use of the word termination in section 12.4 refers to section 11 of the
Agreement, entitled “Termination.” Notably, section 11.1 states that IDR
“shall be entitled to terminate this Agreement, upon written notice to
Physician, at any time for any or no reason.” (emphasis added). Additionally,
section 11.3, entitled, “Effects of Termination” includes a provision that “all
21
duties and obligations of Physician intended to survive termination shall
survive (including Physician’s obligations under Sections . . . 12 . . . of this
Agreement).” Giving effect to all portions of the Agreement and reading it as
a whole, as we must, see Massey Servs., Inc. v. Sanders, 312 So. 3d 209,
214 (Fla. 5th DCA 2021); Anarkali Boutique, Inc. v. Ortiz, 104 So. 3d 1202,
1205–06 (Fla. 4th DCA 2012), we find that the Agreement “contemplated a
situation wherein [Dr. Alonso] remained a[n] [IDR] employee in the absence
of a written agreement.” St. Johns, 22 So. 3d at 733.
Dr. Alonso contends that even if the non-compete provision was in
effect on January 2, 2020, the trial court abused its discretion in finding that
a legitimate business interest justified the non-compete provision. 8 Section
8
Dr. Alonso briefly argues that IDR failed to present evidence that the non-
compete provision was reasonable in area and line of business. See §
542.335(1), Fla. Stat. He asserts that as a result, IDR failed to establish a
prima facie case and the burden never shifted to him to establish that the
provision was overbroad or unreasonable under section 542.335(1)(c). A
claim that IDR did not establish a prima facie case is a challenge to the
sufficiency of the evidence. Dr. Alonso did not argue below that IDR failed
to make a prima facie case that the provision was reasonable as to area and
line of business, and we will not address the argument for the first time on
review. F.B. v. State, 852 So. 2d 226, 229 (Fla. 2003) (“In general, to raise
a claimed error on appeal, a litigant must object at trial when the alleged error
occurs. ‘Furthermore, in order for an argument to be cognizable on appeal,
it must be the specific contention asserted as legal ground for the objection,
exception, or motion below.’” (citation omitted) (quoting Steinhorst v. State,
412 So. 2d 332, 338 (Fla.1982))). Although the sufficiency of the evidence
may be raised on appeal absent preservation by objection or motion below
under Florida Rule of Civil Procedure 1.530(e), that rule applies to judgments
22
542.335(1)(b) sets forth a non-exhaustive list of legitimate business interests
that may justify the restrictive covenant sought to be enforced. See White,
226 So. 3d at 783 (“The statute defines legitimate business interests through
a non-exhaustive list.”). Here, the trial court found that IDR demonstrated a
legitimate business interest in “substantial relationships with specific
prospective or existing customers.” See § 542.335(1)(b)(3) (stating that
“legitimate business interests” includes “[s]ubstantial relationships with
specific prospective or existing customers, patients, or clients”). Dr. Alonso
argues that because he testified that he did not have access to a patient
database at IDR, and Trinidad testified that the names of patients are
confidential and patients are referred to by initials, there was no evidence
presented below to prove the existence of a substantial relationship with
identifiable “specific prospective or existing customers, patients, or clients.”
This argument is without merit. First, the trial court did not find that IDR
proved the existence of a legitimate business interest in substantial
relationships with specific prospective or existing patients, but rather,
entered after civil non-jury trials. See Winchel v. PennyMac Corp., 222 So.
3d 639, 644 (Fla. 2d DCA 2017) (stating that under plain language of rule
1.530(e) “when there has been a nonjury trial and the appellate issue is the
sufficiency of the evidence to support the judgment, the failure to object
based on the insufficiency of the evidence will not bar raising that issue on
appeal”).
23
customers. The finding that IDR had substantial relationships with existing
customers was supported by Trinidad’s testimony that Dr. Alonso had mailed
a letter to IDR’s client requesting work.9 Dr. Alonso acknowledged on cross-
examination that he sent the letter. “‘[T]he right to prohibit the direct
solicitation of existing customers’ is a legitimate business interest, and a
covenant not to compete which includes a non-solicitation clause is
breached when a former employee directly solicits customers of his former
employer.” Atomic Tattoos, LLC, 45 So. 3d at 65 (quoting Dyer v. Pioneer
Concepts, Inc., 667 So. 2d 961, 964 (Fla. 2d DCA 1996)). There is also no
requirement that IDR present evidence of a particular, identifiable existing
customer, client, or patient with which it has a substantial relationship. See
Ansaarie, 252 So. 3d at 290–91 (holding that trial court properly found
hospital demonstrated legitimate business interest in its substantial
relationships with existing patients when it put forth evidence that “a number
of its patients had recently requested to transfer their files to [former
employee/doctor]” and distinguishing its prior holding in University of Florida,
Board of Trustees v. Sanal, 837 So. 2d 512, 516 (Fla. 1st DCA 2003), that a
legitimate business relationship with a prospective patient “must be, in
addition to ‘substantial,’ one with a particular, identifiable, individual”).
9
The parties use the terms “client” and “customer” interchangeably.
24
Because the non-compete provision was in effect when Dr. Alonso began
working for Driven Research, and IDR established as least one legitimate
business interest, 10 the trial court did not err in finding the non-compete
provision valid and enforceable. 11
Dr. Alonso also argues that the temporary injunction is facially deficient
because it does not set forth the act or acts from which he is restrained as
required by Florida Rule of Civil Procedure 1.610(c). On this point, we agree
with Alonso. Rule 1.610(c) provides that an injunction “shall describe in
reasonable detail the act or acts restrained without reference to a pleading
or another document.” “A temporary injunction requires strict compliance
with Florida Rule of Civil Procedure 1.610.” Coscia v. Old Fla. Plantation,
10
Although Dr. Alonso also challenges on appeal the trial court’s finding that
the non-compete provision was supported by legitimate business interests in
valuable confidential business information and specialized training, we need
not address these arguments because section 542.335(1)(b) requires only
that the restrictive covenant be supported by “one or more legitimate
business interests.”
11
We note that IDR was required under section 542.335(1)(c) to also “plead
and prove that the contractually specified restraint is reasonably necessary
to protect the legitimate business interest or interests justifying the
restriction.” Here, the trial court found that the non-compete provision was
reasonably necessary to protect IDR’s legitimate business interests. On
appeal, Dr. Alonso does not challenge the trial court’s finding that the non-
compete provision was “reasonably necessary,” other than to claim that the
burden to establish that the restraint is “overbroad, overlong, or otherwise
not reasonably necessary” never shifted to him. See supra note 7.
25
Ltd., 828 So. 2d 488, 490 (Fla. 2d DCA 2002). With regard to prohibited
conduct, “[o]ne against whom an injunction is directed should not be left in
doubt as to what he is required to do.” 12 Clark v. Allied Assocs., Inc., 477
So. 2d 656, 658 (Fla. 5th DCA 1985). Here, the trial court failed to set forth
in reasonable detail the act or acts Dr. Alonso is enjoined from performing.
Indeed, the temporary injunction does not actually enjoin any activity by Dr.
Alonso. IDR responds that Dr. Alonso knows what conduct is impermissible
because IDR “sought only to enjoin Dr. Alonso from being involved in clinical
research trials related to dermatology.” In support of its argument, IDR cites
to Trinidad’s testimony at the evidentiary hearing. 13 But rule 1.610(c)
12
Relatedly, an injunction may not be enforced by contempt where its terms
are not clear and definite. See Osmo Tec SACV Co. v. Crane Env’t, Inc.,
884 So. 2d 324, 326–27 (Fla. 2d DCA 2004) (“Corollary to the requirement
that enjoined acts be described ‘in reasonable detail’ is the rule that a
contempt sanction may not be imposed for the violation of an injunction
unless the purportedly contemptuous act clearly contravenes the injunction.
Moreover, ‘[a]n essential finding to support contempt is the party’s intent to
violate the court order at issue.’” (citation omitted) (quoting Merrill Lynch Tr.
Co. v. Alzheimer’s Lifeliners Ass’n, 832 So. 2d 948, 954 (Fla. 2d DCA
2002))); see also Penzell v. M & M Constr. Grp. Corp., 915 So. 2d 194, 196
(Fla. 3d DCA 2005) (“When an injunction is sufficiently clear and definite to
apprise the parties of the court’s mandate, the parties must comply or face
the penalty of contempt.”); Tarantola v. Henghold, 233 So. 3d 508, 510 (Fla.
1st DCA 2017).
13
On direct examination, Trinidad testified as follows:
Q: As I – ma’am, as I read your agreement, it only prohibits him
related to dermatological studies; is that correct?
A: Yes.
26
expressly prohibits “reference to a pleading or another document” to
determine the requirements of the temporary injunction. (emphasis added).
Moreover, IDR’s assertion is contradicted by its motion for emergency
injunctive relief, which alleged that Dr. Alonso breached the non-compete
provision when he competed with IDR and solicited IDR’s customers, and
sought a temporary injunction enjoining, among other things, Dr. Alonso from
“attempt[ting] to solicit or solicit or otherwise contact the patients, customers
or clients (including any pharmaceutical companies or manufactures [sic] of
Plaintiff.”14
Q: So if he wants to do a COVID-19 one, he’s free to do that, isn’t
he?
A: Yes.
Q: He -- if he wants to do -- get a Botox practice going, he’s free
to do that, correct?
A: Yes.
Q: There’s only a very limited restriction in what he is not allowed
to do and that is basically to do dermatological studies; is that
correct?
MR. CLANCY: Objection --
A: To do clinical trials in dermatology.
14
In pertinent part, IDR sought to enjoin Dr. Alonso from the following acts:
3. Enjoin Defendant for a period of two (2) years not to directly
or indirectly, on Defendant’s own behalf or as a principal partner,
member, shareholder, officer, employee, agent, consultant,
contractor, physician, director or trustee of any person
partnership, firm association, corporation, hospital, clinic or other
medical facility, engage, perform, conduct, promote, market,
exploit indirectly performs, conducts, promotes, markets, exploits
or engage in or is otherwise involved in, clinical research or trials
27
Accordingly, we reverse the temporary injunction in part with directions
to the trial court to “describe in reasonable detail the act or acts restrained.”
Fla. R. Civ. P. 1.610(c); see also Angelino v. Santa Barbara Enters., LLC, 2
So. 3d 1100, 1104 (Fla. 3d DCA 2009) (finding temporary injunction
defective under rule 1.610(c) where temporary injunction enjoined plaintiff
from “competing against [defendant]” and “usurping [defendant’s] business
opportunities, customers, and suppliers”); Dickerson v. Senior Home Care,
Inc., 181 So. 3d 1228, 1229 (Fla. 5th DCA 2015) (reversing temporary
injunction as facially deficient and remanding for further proceedings where,
among other things, “the trial court’s order does not comply with rule 1.610(c)
because it simply enjoins Appellants ‘from violating their Non–Compete,
Non–Disclosure, Non–Solicitation Agreements’”). We otherwise affirm the
temporary injunction entered below.
Affirmed in part, reversed in part, and remanded.
relating to dermatological including, without limitations,
dermatological products or procedures, anywhere within five (5)
mile radius of the premises provided by the Plaintiff for the
operation of Defendant’s business, attempt to solicit or solicit or
otherwise contact the patients, customers or clients (including
any pharmaceutical companies or manufactures) of Plaintiff or
other physician practices managed by Plaintiff or use patient or
customer lists developed or owned by Plaintiff or other
physicians practices managed by Plaintiff.
28